• About
  • Shop Products
  • Contract Services
    • Contract Services
    • Contract Products
    • Cell Line Information
  • Resources
    • Cell Line Information
    • Antibody Structure
    • InVivoMab vs InVivoPlus
    • Biosimilar Antibodies
    • Immune Checkpoint Antibodies
    • Blog
    • FAQs
  • Contact
  • New Products

Activation of ILC2 expressed GITR ameliorates type 2 diabetes

Follow Us

Posted on March 22, 2019

More Posts

  • Product

    • MAb anti-human/monkey MDR-1 (CD243) (Clone UIC2)

    • 𝙄𝙣𝙑𝙞𝙫𝙤MAb anti-mouse NKG2D (CD314) (Clone CX5)

    • Anti-mouse CTLA-4 (CD152)

    • InVivoMAb anti-mouse/human/rat LRP1 (CD91)

    • InVivoMAb anti-mouse TIGIT

  • Product Highlights

    • MAb anti-mouse CD96 Clone 3.3

    • Anti-mouse PD-1 (CD279) Clone 29F.1A12

    • MAb anti-human MUC1 (CD227) Clone C595 (NCRC48)

    • Anti-mouse CD4 (Clone GK1.5)

    • Anti-mouse Ly6G/Ly6C (Gr-1) (Clone RB6-8C5)

  • Research

    • Hot Immunotherapy Target: OX40

    • Type I IFN Exacerbates Disease in Tuberculosis Susceptible Mice by Inducing Neutrophil-mediated Lung Inflammation and NETosis

    • Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

    • Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression

    • Immunocytokines are a promising immunotherapeutic approach against glioblastoma

  • Publication Highlights

    • Striking a Balance in Anti-tumoral Immunity: A CXCR4 Partial Agonist Overcomes Immune Suppression in Gastric Cancer

    • Literature Insight | How Do Bone Metastases Undermine Immunotherapy?

    • CD16 and CD32 for Fc Receptor Blocking in Flow Cytometry

    • Bio X Cell BE0101 in Action: IL-16 Remodels the Tumor Immune Microenvironment and Boosts Immunotherapy Efficacy

    • In Vivo Depletion of Mouse Neutrophils Using Anti-Ly6G Antibodies

View All Posts

Follow Us

Contact

+65 6747 0201

enquiries@bxcell.sg

48 Toh Guan Road East
#04-138 Enterprise Hub
Singapore 608586

The Latest & Greatest
  • Hot Immunotherapy Target: OX40
  • Type I IFN Exacerbates Disease in Tuberculosis Susceptible Mice by Inducing Neutrophil-mediated Lung Inflammation and NETosis
  • Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
  • Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression
  • Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Information
  • > About
  • > Shop Products
  • > Contract Services
  • > FAQs
  • > Contact
  • Legal Disclaimer
  • Privacy Policy

Copyright © 2020 Bio X Cell All Rights Reserved.

LOADING